Licensing | Collaboration
Archimedes Pharma Ltd has signed a global licensing and development agreement with Almac Discovery Ltd to develop a novel intranasal treatment for chemotherapy-induced nausea using Archimedes’ ChiSys delivery technology. The product has completed pre-clinical proof-of-principle studies, demonstrating that it should provide a rapidly acting, well-tolerated and convenient treatment.
The active ingredient in the drug is the 5-HT3 antagonist granisetron. Whilst this is used to treat chemotherapy-induced nausea currently, it given orally or as an injection. Nasal delivery of granisetron offers the possibility of rapid relief, without injections or oral delivery.
Under the terms of the agreement, Archimedes will be responsible for developing the formulation through to Phase II, and will cooperate with Almac on clinical development of the product. Archimedes will receive a series of milestones and royalties as the product progresses through development to launch.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
